- TRANSITION METAL-COMPLEX CATALYSTS HAVING APPENDED GROUP 13 LEWIS ACIDS AND RELATED POLYMERIZATION METHODS
-
Compositions may comprise symmetrical and asymmetrical pyridine-containing transition metal-complexes having appended group (13) Lewis acids positioned on the pyridine-containing ligands of the transition metal-complex such that the group (13) Lewis acid
- -
-
Paragraph 0118; 0122
(2021/11/06)
-
- TOLL-LIKE RECEPTOR 8 (TLR8)-SPECIFIC ANTAGONISTS AND METHODS OF MAKING AND USES THEREOF
-
Toll-like receptor 8 (TLR8)-specific inhibitors and methods of using the same in individuals having an autoimmune disease or an inflammatory disorder.
- -
-
Page/Page column 49-50; 55
(2019/05/22)
-
- Novel cyclic bicarbodiimide compound and preparation method of novel cyclic bicarbodiimide compound
-
The invention relates to a novel cyclic bicarbodiimide compound (I) and a preparation method of the novel cyclic bicarbodiimide compound. Compared with monocarbodiimide, the novel cyclic bicarbodiimide compound has a higher molecular weight and a higher melting point; the disadvantage that the monocarbodiimide is easily transferred outward from compounds including polyester, polyurethane and like at high temperature is overcome; the anti-hydrolytic property of a material is improved; meanwhile, the defects that an existing bicarbodiimide compound is easily irregularly curled, easily forms a rubber state at room temperature and is not easy to crystallize and purify are overcome; the anti-hydrolytic effect is good and the bicarbodiimide compound has a good anti-hydrolytic property; the service life of a polyester material is improved; the bicarbodiimide compound can be used as an anti-hydrolytic stabilizer and is used for polyurethane and polyester elastomers, and especially can be used for photovoltaic industry, biodegradable materials and the like. The formula (I) is shown in the description.
- -
-
Paragraph 0039
(2017/08/29)
-
- COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES
-
The present invention provides compounds of formula I: [INSERT FORMULA HERE] or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a Plasmodium parasite, such as malaria.
- -
-
Page/Page column 70; 71; 94
(2014/06/11)
-
- NEW INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS
-
The present invention relates to compounds of general formula I, wherein the groups R1, R2 and m are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.
- -
-
Paragraph 0428; 0759-0760
(2013/10/07)
-
- NEW INDANYLOXYDIHYDROBENZOFURANYLACETIC ACID DERIVATIVES AND THEIR USE AS GPR40 RECEPTOR AGONISTS
-
The present invention relates to compounds of general formula I, (I), wherein the groups R1, R2 and m are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.
- -
-
Page/Page column 162
(2013/10/21)
-
- INSECTICIDAL COMPOUNDS
-
A compound of formula (I):wherein A1, A2, A3, A4, R1, R2, R3, R4, G1, G2, Q1, Y1, Y2, Y3 and Y4
- -
-
Page/Page column 31
(2008/06/13)
-